At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
03 juin 2024 07h00 HE
|
Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
22 mai 2024 07h00 HE
|
Achilles Therapeutics PLC
Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
08 mai 2024 07h45 HE
|
Treos Bio Corp.
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...
Promising Personalized Approach to Liver Cancer Therapy Made Possible by DNA-based Neoantigen Research Designed at The Wistar Institute
30 avr. 2024 10h18 HE
|
The Wistar Institute
PHILADELPHIA, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Hepatocellular carcinoma (HCC), or liver cancer, is an aggressive malignancy with limited treatment options. An immunologically cold cancer —...
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines
21 mars 2024 03h00 HE
|
Angelini Ventures
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...
BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten
11 mars 2024 07h45 HE
|
BioNTech SE
MAINZ, Deutschland, 11. März 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom...
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
11 mars 2024 07h45 HE
|
BioNTech SE
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association...
GeoVax Announces Multiple Patent Issuances and Allowances
13 févr. 2024 09h00 HE
|
GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
04 janv. 2024 08h00 HE
|
Enara bio
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicityBoehringer...
Cancer Vaccine Market Size Worth USD 21.39 Billion in 2032 | Emergen Research
02 janv. 2024 08h03 HE
|
Emergen Research
Vancouver, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The global cancer vaccine market demonstrated a robust USD 7.31 Billion in 2022, with expectations of a substantial CAGR of 10.9% throughout the forecast...